Sarepta TherapeuticsSRPT
SRPT
0
Funds holding %
of 6,814 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
19% more call options, than puts
Call options by funds: $285M | Put options by funds: $240M
8% more repeat investments, than reductions
Existing positions increased: 168 | Existing positions reduced: 155
6% less funds holding
Funds holding: 481 [Q2] → 451 (-30) [Q3]
6.47% less ownership
Funds ownership: 98.81% [Q2] → 92.35% (-6.47%) [Q3]
26% less capital invested
Capital invested by funds: $14.8B [Q2] → $11B (-$3.77B) [Q3]
31% less first-time investments, than exits
New positions opened: 58 | Existing positions closed: 84
50% less funds holding in top 10
Funds holding in top 10: 16 [Q2] → 8 (-8) [Q3]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$75
38%
downside
Avg. target
$165
36%
upside
High target
$202
66%
upside
9 analyst ratings
8 positive
89%
0 neutral
0%
1 negative
11%
HC Wainwright & Co. Mitchell Kapoor 26% 1-year accuracy 44 / 167 met price target | 38%downside $75 | Sell Reiterated | 19 Dec 2024 |
Piper Sandler Biren Amin 10% 1-year accuracy 2 / 20 met price target | 49%upside $182 | Overweight Maintained | 27 Nov 2024 |
Needham Gil Blum 24% 1-year accuracy 40 / 169 met price target | 66%upside $202 | Buy Maintained | 27 Nov 2024 |
Guggenheim Whitney Ijem 23% 1-year accuracy 9 / 40 met price target | 23%upside $150 | Buy Maintained | 7 Nov 2024 |
Baird Brian Skorney 17% 1-year accuracy 4 / 24 met price target | 59%upside $193 | Outperform Maintained | 7 Nov 2024 |
Financial journalist opinion
Based on 9 articles about SRPT published over the past 30 days
Neutral
PRNewsWire
6 days ago
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference
LUND, Sweden , Jan. 7, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced that management will attend the 43rd Annual J.P. Morgan Healthcare Conference.
Positive
Zacks Investment Research
1 week ago
SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell?
The upside in Sarepta's share price can be attributed to the encouraging sales performance of its DMD gene therapy, which has demonstrated blockbuster potential.
Neutral
Business Wire
1 week ago
Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. on Monday, Jan. 13, 2025 at 12:00 p.m. E.T. / 9:00 a.m. P.T. Following the presentation there will be a Q&A session starting at 12:20 p.m. E.T. / 9:20 a.m. P.T. The presentation will be webcast live under the Events & Presen.
Neutral
Business Wire
1 week ago
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired by Sarepta in December 2024. The equity awards were approved in accordance with Nasdaq List.
Positive
Reuters
3 weeks ago
Sarepta wins $115.2 million US drug patent verdict from Japan's Nippon Shinyaku
Japanese drugmaker Nippon Shinyaku infringed a Sarepta patent related to its Duchenne muscular dystrophy (DMD) drug Vyondys 53 and must pay $115.2 million in damages, a Delaware jury said on Friday.
Positive
Zacks Investment Research
3 weeks ago
4 Biotech Stocks Most Wall Street Analysts Are Bullish About
Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundamentals.
Neutral
Zacks Investment Research
3 weeks ago
SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder
The phase III EMERGENE study evaluates Sarepta's experimental gene therapy for an ultra-rare form of muscle disorder for which there is no treatment beyond symptom management.
Neutral
Business Wire
3 weeks ago
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that enrollment and dosing is complete in EMERGENE (Study SRP-9003-301), a Phase 3 clinical trial of SRP-9003 (bidridistrogene xeboparvovec). SRP-9003 is an investigational gene therapy for the treatment of limb-girdle muscular dystrophy Type 2E/R4 (LGMD2E/R4), or beta-sarcoglycanopathy. EMERGENE is a global study, and the primary endpoint is t.
Positive
Zacks Investment Research
3 weeks ago
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
We have picked three biotech stocks with promising gene therapies in their portfolios/pipelines that are likely to perform well in 2025.
Positive
Proactive Investors
1 month ago
FDA's new accelerated approval guidance to benefit rare disease drug development, analysts believe
New Food and Drug Administration (FDA) guidance on accelerated approval for drugs targeting “serious conditions” appears to be a positive move for rare diseases, analysts at Jefferies believe. The FDA earlier this month published the draft guidance on its policies and procedures for the accelerated approval (AA) pathway for drugs for serious conditions that fulfil an unmet medical need.
Charts implemented using Lightweight Charts™